PULMONARY SURFACTANT MARKET ANALYSIS

Market Challenges And Opportunities

Pulmonary Surfactant Market-Drivers

Increasing preference of animal derived surfactant for the treatment of respiratory distress syndrome is driving the pulmonary surfactant market growth over the forecast period.

Increasing preference of animal derived surfactant for the treatment of respiratory distress syndrome is driving the pulmonary surfactant market growth over the forecast period. For instance, in May 2021, according to the article published in Archives of Clinical and Medical Case Reports, an open access, peer reviewed Journal, Poractant alfa (Curosurf), significantly reduced the rates of pneumothorax (the presence of air or gas in the cavity between the lungs and the chest wall, causing collapse of the lung) in preterm infants with respiratory distress syndrome. This reduction was more significant in VLBW (very low birth weight) than non-VLBW (very low birth weight) infants.

Furthermore, on April 11, 2022, an article was published in National Center for Biotechnology Information, a branch of the National Institutes of Health, which reported that when animal derived pulmonary surfactant is combined with budesonide, a corticosteroid or steroid, in the treatment of neonatal respiratory distress syndrome can effectively shorten the hospital stay and reduce the time of invasive mechanical ventilation and the incidence of BPD (bronchopulmonary dysplasia). Meanwhile, it does not increase the risk of related complications or death. This approach can be applied clinically.

Pulmonary Surfactant Market-Restraints

Increasing number of side effect associated with the pulmonary surfactant drug restrain the growth of pulmonary surfactants market. The drugs used in the treatment of respiratory disorders have several side effects. For instance according to a report published by RxList Inc, an online medical resource offering detailed and current pharmaceutical information on brand and generic drugs, on March 3, 2022, common side effects of Surfaxin, a liquid medication used to treat infant respiratory distress syndrome, are related to its administration down a premature infant's breathing tube (endotracheal tube) and include endotracheal tube reflux, skin paleness, endotracheal tube obstruction, and need for dose ductus arteriosus and lung problems.